Octapharma Partners With Apexus to Provide IGIV at Sub-340B Price

by Admin | August 1, 2012 3:00 pm

August 1, 2012—Octapharma USA’s octagam 5% immune globulin intravenous (IGIV) therapy is now available at sub-340B pricing to participants in the Apexus/340B Prime Vendor Program (PVP).

Apexus Director of Contract Services John Barnes made the announcement in a July 30 email to PVP participants. 

You must be registered to read complete articles (it's quick, easy, and 100% free). Click here to register[1].    Already registered? Click here to login[2]. (340B Health members, Drug Discount Monitor subscribers, and 340B Coalition conference attendees: Use your existing username and password.)

 

Endnotes:
  1. Click here to register: https://secure.340bhealth.org/340Binformed/Subscribe.aspx
  2. Click here to login: http://340binformed.org/reader-login/

Source URL: https://340binformed.org/2012/08/octapharma-partners-with-apexus-to-provide-igiv-at-sub-340b-price/

Copyright ©2026 340binformed.org unless otherwise noted.